Clinical study
PHAGE Study: Bacteriophages as Novel Prebiotics
| Status | Completed |
|---|---|
| Type | Adjacent product trial |
| Countries | Location not listed |
| Conditions studied | Gastrointestinal Disorder, Functional |
| Study years | 2016–2017 |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
Inclusion Criteria: * Healthy adults * 18-65 years old * Mild to moderate GI distress (self-assessed) Exclusion Criteria: * Pregnant or breastfeeding * Diagnosed GI disease (Celiac, peptic ulcer, ulcerative colitis, Crohn's disease, cancer, or other gastrointestinal or metabolic diseases) * Antibiotic use in the past 2 months * Use of NSAIDS, statins, metformin, and other drugs known to modify the gut microbiota * BMI less than 18.0 or greater than 35.0
Study description
The PHAGE study is designed to determine if a commercial prebiotic product can change the composition of bacteria in the gut for improved intestinal health. A prebiotic is defined as an indigestible dietary component that selectively enhances specific bacterial species in the intestines to confer a health benefit. In this study, the prebiotic a unique combination of bacteriophages, or viruses that infect bacteria. These phages are generally regarded as safe for human consumption and work by infecting bad bacteria in the gut, which allows beneficial bacteria populations to increase. The product, PreforPro, has shown to be effective in culture-based and animal studies, but its efficacy has not been demonstrated in humans. The goal of this study is to see if PreforPro consumption improves gut bacteria profiles in individuals relative to a placebo control and is associated with reduced incidence and severity of gastrointestinal distress.
Study registrations
| ClinicalTrials.gov | NCT03269617 |
|---|
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct03269617 |
|---|